Loading...
Loading...
ORIC| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.3M |
| Gross Profit | -0.3M |
| Operating Expense | 25.0M |
| Operating I/L | -25.0M |
| Other Income/Expense | 2.0M |
| Interest Income | 2.0M |
| Pretax | -22.9M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -22.9M |
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for the treatment of cancers in the United States. The company's clinical stage product candidates, including ORIC-533, ORIC-944, and ORIC-114, target specific cancer resistance mechanisms, such as CD73 inhibition and polycomb repressive complex 2 inhibition. These products are designed to address resistance to chemotherapy- and immunotherapy-based treatment regimens, as well as target specific mutations in cancer cells. ORIC Pharmaceuticals also has license and collaboration agreements with Voronoi Inc. and Mirati Therapeutics, Inc., which contribute to its revenue stream.
